The records of all renal transplant patients at our hospital from May 1994 until November 2000 were reviewed retrospectively. A Total of 45 of 56 hospital records were successfully retrieved. Criteria for diagnosis included presence of symptoms and signs of laboratory abnormalities plus at least one of the following indications of CMV infection: (1) CMV IgM titer equal to or greater than 1:10 or fourfold rise in CMV IgG titer; (2) detection of CMVantigenemia by CMV-specific antigen. The maintenance immunosuppression regimens in all patients consisted of azathioprine-prednisoe and cyclosporine. Ten patients received quadruple therapy including ATG for a period of 2 weeks. CMV disease was documented in 14 patients (9 males) aged 44.16 +-15.28 years. The median interval between transplantation and development of CMV disease was 4 months. 9 cases had received anti rejection treatment in the 3 months period preceeding the diagnosis. Symptomatic CMV infection is relatively common in our patients. Among such patients, previous polyclonal antilymphocyte antibody treatment is associated with more severe CMV infection, and more patients in the severe group require treatment with IV ganciclovir.